← 홈

ADC

60개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 60개
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19A (SGN-CD19A)

Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 ACTIVE
ADCBiologicPfizerPhase 2

ALLR3 (ALLR3)

ACUTE LYMPHOBLASTIC LEUKEMIA · ACUTE LYMPHOBLASTIC LEUKEMIA

#ACUTELYMPHOBLASTICLEUKEMIA#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 3상태 RECRUITING
ADCBiologicstaleGruppo Italiano Malattie EMatol…Phase 3

Gilteritinib Fumarate (Gilteritinib Fumarate)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 3상태 RECRUITING
ADCBiologicAstraZenecaPhase 2

AZD4512 monotherapy (AZD4512 monotherapy)

B-cell Acute Lymphoblastic Leukemia (B-ALL) · B-cell Acute Lymphoblastic Leukemia (B-A

#B-cellAcuteLymphoblasticLeukemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstaleAmgenPhase 2

Blinatumomab and Inotuzumab Ozogamicin (Blinatumomab and Inotuzumab Ozogamicin)

Acute Lymphoblastic Leukemia; Immunotherapy · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleEverett MeyerPhase 2

CliniMACS CD34 Reagent System (CliniMACS CD34 Reagent System)

Leukemia, Acute; Chronic Myelogenous Leukemia (CML) · CD3

#CD3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 DISCONTINUED
ADCBiologicstalePfizerPreclinical

GO (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (GO))

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 1

High dose cytarabine for consolidation (High dose cytarabine for consolidation)

Acute Myeloid Leukemia; Acute Myelogenous Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleInstitut Paoli-CalmettesPhase 1

INA03 administration (INA03 administration)

Acute Lymphoblastic Leukemia Recurrent; Acute Lymphoblastic Leukemia, in Relapse · Acute Lymphoblastic Leukemia Recurrent

#AcuteLymphoblasticLeukemiaRecurr#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
ADCBiologicstalePfizerApproved

Inotuzumab ozogamicin-dose level 1 (Inotuzumab ozogamicin-dose level 1)

Leukemia; Precursor b-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia

#Leukemia#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleNovartis PharmaceuticalsPhase 1

JBH492 (JBH492)

Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
ADCBiologicstalePfizerPhase 2

Mylotarg (Mylotarg)

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 RECRUITING
ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

STI-6129 (Part 1, Part 1 (STI-6129))

Refractory T Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia (AML) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleM.D. Anderson Cancer CenterPhase 1

STI-6129 (Part 2, Part 2 (STI-6129))

Refractory T Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia (AML) · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleServier Bio-Innovation LLCPhase 2

S227928 (S227928)

Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)/AML · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 DISCONTINUED
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD123A (SGN-CD123A)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 DISCONTINUED
ADCBiologicstaleSeagen Inc.Phase 1

Standard dose cytarabine for induction (Standard dose cytarabine for induction)

Acute Myeloid Leukemia; Acute Myelogenous Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleShaare Zedek Medical CenterPhase 2

Vyxeos (Vyxeos)

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 RECRUITING
ADCBiologicstalePfizerApproved

inotuzumab ozogamicin-dose level 2 (inotuzumab ozogamicin-dose level 2)

Leukemia; Precursor b-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia

#Leukemia#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleNew York Medical CollegePhase 1

pralatraxate, (pralatraxate,)

NK-Cell Lymphoma; NK-Cell Leukemia · NK-Cell Lymphoma

#NK-CellLymphoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING

3 / 3 페이지

← 이전다음 →